Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Orphanet Journal of Rare Diseases

Figure 1

From: Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis

Figure 1

Antibiofilm activity against P. aeruginosa PAO1 Biofilms of A – cysteamine, N-Acetylcysteine, rhDNase and alginate lyase and B – cysteamine and cysteamine in combination with tobramycin. A- a: Untreated control; b: 1 mg/ml Cysteamine; c: 1 mg/ml N-acetylcysteine; d: 1 mg/ml Cysteamine hydrochloride; e: 1 mg/ml rhDNase I; f: 1 mg/ml Alginate lyase. B- a: Control 0 h; b: Control 16 h; c: 100 μg/ml cysteamine; d: 10 μg/ml tobramycin; e: 100 μg/ml cysteamine & 10 μg/ml tobramycin. In all cases, P. aeruginosa PAO1 biofilms were seeded, and their growth monitored, in the presence of the mucoactive and/or antibacterial compounds listed above for 16 h in the BioFlux200 microfluidic system at a flow rate of 0.5 Dyn/cm2.

Back to article page